1st Faculty of Medicine Charles University 1st Faculty of Medicine Charles University Lymphoma Lab
14.12.2020

Manuscripts:

2020

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.

Pytlik R, Polgarova K, Karolova J, Klener P.

Vaccines (Basel). 2020 Nov 27;8(4):E708. doi: 10.3390/vaccines8040708.

CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

Vockova P, Molinsky J, Klanova M, Karban J, Spacek M, Havranek O, Kupcova K, Kazantsev D, Trneny M, Klener P.

Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678. Online ahead of print.

Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma.

Pola R, Pokorná E, Vočková P, Böhmová E, Pechar M, Karolová J, Pankrác J, Šefc L, Helman K, Trněný M, Etrych T, Klener P.

Acta Biomater. 2020 Nov 11:S1742-7061(20)30657-7. doi: 10.1016/j.actbio.2020.11.014. Online ahead of print.

Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.

Štach M, Ptáčková P, Mucha M, Musil J, Klener P, Otáhal P.

Cytotherapy. 2020 Dec;22(12):744-754. doi: 10.1016/j.jcyt.2020.08.005. Epub 2020 Sep 17.

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.

Pytlík R, Vacková B, Konířová E, Trnková M, Blahovcová P, Pohlreich D, Polgárová K, Klener P Jr, Benešová K, Kopečková K, Pirnos J, Trněný M.

Bone Marrow Transplant. 2020 Sep 3. doi: 10.1038/s41409-020-01045-4. Online ahead of print.

A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.

Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, Jirkuvova A, Petrackova A, Malarikova D, Forsterova K, Cudova B, Sedlarikova L, Berkova A, Kasalova N, Papajik T, Trneny M.

Br J Haematol. 2020 Aug 30. doi: 10.1111/bjh.17063. Online ahead of print.

Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab.

Lidický O, Klener P, Machová D, Vočková P, Pokorná E, Helman K, Mavis C, Janoušková O, Etrych T.

J Control Release. 2020 Aug 27;328:160-170. doi: 10.1016/j.jconrel.2020.08.042. Online ahead of print.

Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.

Klener P.

Expert Opin Ther Targets. 2020 Oct;24(10):1029-1045. doi: 10.1080/14728222.2020.1813718. Epub 2020 Aug 31.

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.

Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K, Kriegova E, Prihodova E, Pavlistova L, Petrackova A, Zemanova Z, Trneny M, Klener P.

Cancers (Basel). 2020 Jul 31;12(8):2120. doi: 10.3390/cancers12082120.

Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.

Vockova P, Svaton M, Karolova J, Pokorna E, Vokurka M, Klener P.

Folia Biol (Praha). 2020;66(1):17-23.

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).

Janikova A, Michalka J, Bortlicek Z, Chloupkova R, Campr V, Kopalova N, Klener P, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Trneny M.

Ann Hematol. 2020 Jul;99(7):1583-1594. doi: 10.1007/s00277-020-04099-y. Epub 2020 Jun 6.

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.

Klanova M, Klener P.

Cancers (Basel). 2020 Apr 10;12(4):938. doi: 10.3390/cancers12040938.

Drug Resistance in Non-Hodgkin Lymphomas.

Klener P, Klanova M.

Int J Mol Sci. 2020 Mar 18;21(6):2081. doi: 10.3390/ijms21062081.

Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Lemm EA, Valle-Argos B, Smith LD, Richter J, Gebreselassie Y, Carter MJ, Karolova J, Svaton M, Helman K, Weston-Bell NJ, Karydis L, Williamson CT, Lenz G, Pettigrew J, Harwig C, Stevenson FK, Cragg M, Forconi F, Steele AJ, Cross J, Mackenzie L, Klener P, Packham G.

Clin Cancer Res. 2020 Apr 1;26(7):1700-1711. doi: 10.1158/1078-0432.CCR-19-2202. Epub 2019 Dec 12.

Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.

Bucher P, Erdmann T, Grondona P, Xu W, Schmitt A, Schürch C, Zapukhlyak M, Schönfeld C, Serfling E, Kramer D, Grau M, Klener P, Lengerke C, Schulze-Osthoff K, Lenz G, Hailfinger S.

Blood. 2020 Jan 9;135(2):121-132. doi: 10.1182/blood.2019001866.

2019

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.

Klener P.

Int J Mol Sci. 2019 Sep 8;20(18):4417. doi: 10.3390/ijms20184417.

Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Lemm EA, Valle-Argos B, Smith LD, Richter J, Gebreselassie Y, Carter MJ, Karolova J, Svaton M, Helman K, Weston-Bell NJ, Karydis L, Williamson CT, Lenz G, Pettigrew J, Harwig C, Stevenson FK, Cragg M, Forconi F, Steele AJ, Cross J, Mackenzie L, Klener P, Packham G.

Clin Cancer Res. 2020 Apr 1;26(7):1700-1711. doi: 10.1158/1078-0432.CCR-19-2202. Epub 2019 Dec 12.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.

Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry.

Obr A, Prochazka V, Papajik T, Klener P Jr, Janikova A, Salek D, Belada D, Pytlík R, Sykorova A, Mocikova H, Simkovic M, Campr V, Dlouha J, Furst T, Trněný M.

Leuk Lymphoma. 2019 Mar;60(3):748-755. doi: 10.1080/10428194.2018.1508672. Epub 2018 Sep 6.

Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.

Klener P Jr, Etrych T, Klener P.

Curr Med Chem. 2019;26(6):1002-1018. doi: 10.2174/0929867324666171006144725.

3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.

Jorda R, Havlíček L, Šturc A, Tušková D, Daumová L, Alam M, Škerlová J, Nekardová M, Peřina M, Pospíšil T, Široká J, Urbánek L, Pachl P, Řezáčová P, Strnad M, Klener P, Kryštof V.

J Med Chem. 2019 May 9;62(9):4606-4623. doi: 10.1021/acs.jmedchem.9b00189. Epub 2019 Apr 17.

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.

Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M.

Ann Hematol. 2019 Aug;98(8):1961-1972. doi: 10.1007/s00277-019-03694-y. Epub 2019 May 8.

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, Campr V, Prochazka V, Obr A, Jaksa R, Kuntscherova J, Boudová L, Kodet R, Janikova A, Trneny M.

Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13.

A three-pronged "Pitchfork" strategy enables an extensive description of the human membrane proteome and the identification of missing proteins.

Vit O, Harant K, Klener P, Man P, Petrak J.

J Proteomics. 2019 Jul 30;204:103411. doi: 10.1016/j.jprot.2019.103411. Epub 2019 Jun 6.

2018

Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging.

Etrych T, Daumová L, Pokorná E, Tušková D, Lidický O, Kolářová V, Pankrác J, Šefc L, Chytil P, Klener P.

J Control Release. 2018 Nov 10;289:44-55. doi: 10.1016/j.jconrel.2018.09.018. Epub 2018 Sep 22.

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.

Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, Duras J, Mocikova H, Trneny M.

Leuk Res. 2018 Oct;73:29-38. doi: 10.1016/j.leukres.2018.08.019. Epub 2018 Aug 31.

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M.

Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13.

Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.

Lokvenc M, Kalinova M, Forsterova K, Klener P, Trneny M, Fronkova E, Kodet R.

Ann Hematol. 2018 Mar;97(3):467-474. doi: 10.1007/s00277-017-3210-8. Epub 2017 Dec 22.

Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female.

Patzelt M, Zarubova L, Klener P, Barta J, Benkova K, Brandejsova A, Trneny M, Gürlich R, Sukop A.

Aesthetic Plast Surg. 2018 Apr;42(2):451-455. doi: 10.1007/s00266-017-1012-y. Epub 2017 Nov 3.

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.

Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30.

2017

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Feb 15. pii: blood-2016-12-758599. doi: 10.1182/blood-2016-12-758599.

Hematopoiesis in patients with mature B cell malignancies is deregulated even in patients with undetectable bone marrow involvement.

Maswabi BC, Molinsky J, Savvulidi F, Zikmund T, Prukova D, Tuskova D, Klanova M, Vockova P, Lateckova L, Sefc L, Zivny J, Trneny M, Klener P.

Haematologica. 2017 Jan 5. pii: haematol.2016.151571. doi: 10.3324/haematol.2016.151571.

 

2016

B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2016 Nov 18. pii: blood-2016-05-718775.

Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.

Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, Soukup J, Kulvait V, Vargova J, Fiser K, Prukova D, Alam M, Calvin Lenyeletse Maswabi B, Michalova K, Zemanova Z, Jancuskova T, Pekova S, Trneny M

Int J Cancer. 2016 Nov 15;139(10):2252-60.

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.

Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T.

Blood Cancer J. 2016 Sep 23;6(9):e475.

Significantly higher numbers of proB cells in healthy Caucasians compared to Asians: Is there association with incidence of CLL?

Molinsky J, Maswabi B, Prukova D, Klanova M, Vockova P, Zikmund T, Savvulidi F, Alam M, Sefc L, Vokurka M, Obrtlikova P, Trneny M, Klener P Jr.

Blood Cells Mol Dis. 2016 Mar;57:118-9.

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ.

Blood. 2016 Mar 3;127(9):1128-37.

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.

Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman K, Vockova P, Lateckova L, Molinsky J, Maswabi BC, Alam M, Kodet R, Pytlik R, Trneny M, Klener P.

Clin Cancer Res. 2016 Mar 1;22(5):1138-49.

Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model.

Klanova M, Soukup T, Molinsky J, Lateckova L, Vockova P, Alam M, Zivny J, Trneny M, Klener P.

Neoplasma. 2016;63(5):774-8.

2015

Anti-Lymphoma Efficacy Comparison of Anti-CD20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.

Lidický O, Janoušková O, Strohalm J, Alam M, Klener P, Etrych T.

Molecules. 2015 Nov 4;20(11):19849-64.

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.

Otáhal P, Průková D, Král V, Fabry M, Vočková P, Latečková L, Trněný M, Klener P.

Oncoimmunology. 2015 Dec 3;5(4):e1115940.

Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.

Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, Vockova P, Maswabi B, Klener P Jr, Petrak J.

PLoS One. 2015 Aug 18;10(8):e0135314.

Immunotherapy Approaches in Cancer Treatment.

Klener P Jr, Otáhal P, Lateckova L, Klener P.

Curr Pharm Biotechnol. 2015;16(9):771-81.

The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma.

Kalinova M, Fronkova E, Klener P, Forsterova K, Lokvenc M, Mejstrikova E, Belada D, Mocikova H, Trneny M, Kodet R, Trka J.

Br J Haematol. 2015 Apr;169(1):145-8.

Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.

Pytlík R, Belada D, Kubáčková K, Vášová I, Kozák T, Pirnos J, Bolomská I, Matuška M, Přibylová J, Campr V, Burešová L, Sýkorová A, Berková A, Klener P, Trněný M; Czech Lymphoma Study Group.

Leuk Lymphoma. 2015 Jan;56(1):57-64.

2014

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr.

Mol Cancer. 2014 Jun 27;13:159.

Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.

Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi BC, Prukova D, Brezinova J, Michalova K, Vockova P, Hernandez-Ilizaliturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P.

Lab Invest. 2014 Jul;94(7):806-17.

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.

Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S, Jankovska M, Pytlik R, Belada D, Pirnos J, Moulis M, Kodet R, Michal M, Janousova E, Muzik J, Mayer J, Trněný M.

Leuk Lymphoma. 2014 Apr;55(4):802-10.

2013

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.

Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; European Mantle Cell Lymphoma Network.

Ann Oncol. 2013 Aug;24(8):2119-23.,

In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1.

Molinský J, Klánová M, Maswabi B, Soukup T, Trněný M, Nečas E, Živný J, Klener P.

Folia Biol (Praha). 2013;59(1):26-31.

Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes.

Pospisilova J, Vit O, Lorkova L, Klanova M, Zivny J, Klener P, Petrak J.

Int J Mol Med. 2013 May;31(5):1273-9.

The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.

Beranova L, Pombinho AR, Spegarova J, Koc M, Klanova M, Molinsky J, Klener P, Bartunek P, Andera L.

Apoptosis. 2013 Jun;18(6):739-50.

Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL).

Leahomschi S, Molinsky J, Klanova M, Andera L, Peterka M, Gasova Z, Klener P Sr, Trneny M, Necas E, Simonova T, Zivny J, Klener P Jr.

Neoplasma. 2013;60(2):223-31.

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; European MCL Network.

Leuk Lymphoma. 2013 Apr;54(4):699-707.

Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Molinsky J, Klanova M, Koc M, Beranova L, Andera L, Ludvikova Z, Bohmova M, Gasova Z, Strnad M, Ivanek R, Trneny M, Necas E, Zivny J, Klener P.

Leuk Lymphoma. 2013 Feb;54(2):372-80.

2012

Molecularly-targeted and biological anti-cancer therapy.

Klener P Jr, Klener P.

Folia Biol (Praha). 2012;58(1):1-6.

N-phosphonocarbonylpyrrolidine derivatives of guanine: a new class of bi-substrate inhibitors of human purine nucleoside phosphorylase.

Rejman D, Panova N, Klener P, Maswabi B, Pohl R, Rosenberg I.

J Med Chem. 2012 Feb 23;55(4):1612-21.

Intrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report.

Klanova M, Klener P, Trneny M, Straub J, Spicka I.

Case Reports Immunol. 2012;2012:978479.

2010

The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.

Zivny J, Klener P Jr, Pytlik R, Andera L.

Curr Pharm Des. 2010 Jan;16(1):11-33.

2009

Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts.

Petrak J, Toman O, Simonova T, Halada P, Cmejla R, Klener P, Zivny J.

Proteomics. 2009 Nov;9(22):5006-15.

The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering.

Pytlík R, Stehlík D, Soukup T, Kalbácová M, Rypácek F, Trc T, Mulinková K, Michnová P, Kideryová L, Zivný J, Klener P Jr, Veselá R, Trnený M, Klener P.

Biomaterials. 2009 Jul;30(20):3415-27.

TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine.

Klener P Jr, Leahomschi S, Molinsky J, Simonova T, Necas E, Gasova Z, Cermak J, Dolezalova L, Andera L, Zivny J.

Blood Cells Mol Dis. 2009 Jan-Feb;42(1):77-84.

2007

Complete suppression of viral gene expression is associated with the onset and progression of lymphoid malignancy: observations in Bovine Leukemia Virus-infected sheep.

Merimi M, Klener P, Szynal M, Cleuter Y, Bagnis C, Kerkhofs P, Burny A, Martiat P, Van den Broeke A.

Retrovirology. 2007 Jul 23;4:51.

Suppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code.

Merimi M, Klener P, Szynal M, Cleuter Y, Kerkhofs P, Burny A, Martiat P, Van den Broeke A.

J Virol. 2007 Jun;81(11):5929-39. Epub 2007 Mar 28.

2006

Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of therapeutic approaches.

Klener P Jr, Andera L, Klener P, Necas E, Zivný J.

Folia Biol (Praha). 2006;52(4):119-36.

Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of apoptotic pathways.

Klener P Jr, Andera L, Klener P, Necas E, Zivný J.

Folia Biol (Praha). 2006;52(1-2):34-44.

Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells.

Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A, Martiat P, Van den Broeke A.

J Virol. 2006 Feb;80(4):1922-38.

number of views: 2175 last modification: 14.12.2020
Page ranking: If you think the article is not up-to-date, click here.